



#5

Attorney Docket No. 5405.225

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Boustany, et al.
Serial No.: 09/830,045
Filed: 20 April 2001
For: METHODS OF SCREENING FOR RISK OF PROLIFERATIVE DISEASE
AND METHODS FOR THE TREATMENT OF PROLIFERATIVE
DISEASE

May 15, 2002


Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665



20792


PATENT TRADEMARK OFFICE

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, DC 20231 on May 15, 2002.


Vickie Diane Prior

Date of Signature: May 15, 2002

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		09/830,045	
		Filing Date		April 20, 2001	
		First Named Inventor		Rose-Mary N. Boustany	
		Group Art Unit		Unknown	
Examiner Name		Unknown			
Sheet	1	of	3	Attorney Docket Number	5405.225

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	4,599,308		Hamer et al.	7/8/86	
	2	4,797,368		Carter et al.	1/10/89	
	3	5,139,941		Muzyczka et al.	8/18/92	
	4	5,173,414		Lebkowski et al.	12/22/92	
	5	5,176,996		Hogan et al.	1/5/93	
	6	5,252,479		Srivastava	10/12/93	
	7	5,288,514		Ellman	2/22/94	
	8	5,354,678		Lebkowski et al.	10/11/94	
	9	5,436,146		Shenk et al.	7/25/95	
	10	5,445,934		Fodor et al.	8/29/95	
	11	5,468,634		Liu	11/21/95	
	12	5,474,935		Chatterjee et al.	12/12/95	
	13	5,518,913		Massie et al.	5/21/96	
	14	5,565,324		Still et al.	10/15/96	
	15	5,585,269		Earp, III et al.	12/17/96	
	16	5,585,362		Wilson et al.	12/17/96	
	17	5,587,308		Carter et al.	12/24/96	
	18	5,589,477		Chokai et al.	12/31/96	
	19	5,604,090		Alexander et al.	2/18/97	
	20	5,616,326		Spibey	4/1/97	
	21	5,622,856		Natsoulis	4/22/97	
	22	5,650,316		Aggarwal et al.	7/22/97	
	23	5,658,776		Flotte et al.	8/19/97	
	24	5,670,488		Gregory et al.	9/23/97	
	25	5,677,158		Zhou et al.	10/14/97	
	26	5,681,731		Lebkowski et al.	10/28/97	
	27	5,707,865		Kohn et al.	1/13/98	
	28	5,734,039		Calabretta et al.	3/31/98	
	29	5,747,335		Haseloff et al.	5/5/98	
	30	5,766,942		Haseloff et al.	6/16/98	
	31	5,773,260		Goldberg et al.	6/30/98	
	32	5,811,537		Griesen	9/22/98	
	33	5,817,635		Eckstein et al.	10/6/98	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				T
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	34	Altschul, et al., <i>Basic Local Alignment Search Tool</i> , J. Mol. Biol., Vol. 215, pp. 403-410 (1990)		
	35	Amarnath, et al., <i>Chemical Synthesis of Oligonucleotides</i> , Chemical Reviews, Vol. 77, No. 2, pp. 193-217 (1977)		
	36	Andersson, et al., <i>Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme</i> , Journal of Biological Chemistry, Vol. 264, No. 14, pp. 8222-8229 (1989)		
	37	Arends, et al., <i>Apoptosis: The Role of the Endonuclease</i> , American Journal of Pathology, Vol. 136, No. 3, pp. 593-608		


Substitute form 1449A/PTO		Complete if Known	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 Of 3



Application Number 09/830,045
Filing Date April 20, 2001
First Named Inventor Rose-Mary N. Boustany
Group Art Unit Unknown
Examiner Name Unknown
Attorney Docket Number 5405.225

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	38	Atherton, et al., <i>The Solid Phase in Solid-Phase Synthesis, Perspectives in Peptide Chemistry</i> , pp. 101-117 (Karger, Basel 1981)	
	39	Bligh, et al., <i>A Rapid Method of Total Lipid Extraction and Purification, Canadian Journal of Biochemistry and Physiology</i> , Vol. 37, No. 8, pp. 911-917 (August 1959)	
	40	Boustany, et al., <i>Neurological Progress - The Neuronal Ceroid Lipofuscinoses: A Review, Revue Neurologique</i> , Vol. 145, No. 2, pp. 105-110 (1989)	
	41	Boustany, Rose-Mary, <i>Neurology of the Neuronal Ceroid-Lipofuscinoses: Late Infantile and Juvenile Types, American Journal of Medical Genetics</i> , Vol. 42, pp. 533-535 (1992)	
	42	Boustany, et al., <i>Clinical Classification of Neuronal Ceroid-Lipofuscinosis Subtypes, American Journal of Medical Genetics Supplement</i> , Vol. 5, pp. 47-58 (1988)	
	43	Fieck, et al., <i>Modifications of the E. coli Lac repressor for expression in eukaryotic cells: effects of nuclear signal sequences on protein activity and nuclear accumulation, Nucleic Acids Research</i> , Vol. 20, No. 7, pp. 1785-1791 (April 11, 1992)	
	44	Friedmann, Theodore, <i>Progress Toward Human Gene Therapy, Science</i> , Vol. 244, pp. 1275-1281 (June 16, 1989)	
	45	Fridkin, Mati, <i>Polymeric Reagents in Peptide Synthesis, The Peptides</i> , Vol. 2, pp. 333-363 (1979)	
	46	Stoll, et al., <i>Effect of Vincristine on Sister Chromatid Exchanges of Normal Hyman Lymphocytes, Cancer Research</i> , Vol. 36, pp. 2710-2713 (August 1976)	
	47	Howard, et al., <i>Cell Cycle Arrest of Proliferating Neuronal Cells by Serum Deprivation Can Result in Either Apoptosis or Differentiation, Journal of Neurochemistry</i> , Vol. 60, No. 5, pp. 1783-1791 (May 1993)	
	48	Kaufmann, et al., <i>Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis, Cancer Research</i> , pp. 3976-3985 (September 1, 1993)	
	49	Obeid, et al., <i>Programmed Cell Death Induced by Ceramide, Science</i> , Vol. 259, pp. 1769-1771 (March 19, 1993)	
	50	Perry, et al., <i>Bcl-2 acts upstream of the PARP protease and prevents it activation, Cell Death and Differentiation</i> , Vol. 4, No. 1, pp. 29-33 (1997)	
	51	Rosenbaum, et al., <i>Evidence of Hypoxia-induced, Programmed Cell Death of Cultured Neurons, Annals of Neurology</i> , Vol. 36, No. 6, pp. 864-870	
	52	Walker, P. Roy, et al., <i>Topoisomerase II-reactive Chemotherapeutic Drugs Induce Apoptosis in Thymocytes, Cancer Research</i> , Vol. 51, No. 4, pp. 1078-1085 (February 15, 1991)	
	53	Woo, Savio L.C., <i>Adenovirus redirected, Nature Biotechnology</i> , Vol. 14, No. 11, pp. 1538 (November 1996)	
	54	Lee, et al., <i>Ceramide Inactivates Cellular Protein Kinase Cα*, Journal of Biological Chemistry</i> , Vol. 271, No. 22, pp. 13169-13174 (May 31, 1996)	
	55	Zhang, et al., <i>Bcl-2 interrupts the ceramide-mediated pathway of cell death, Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 5325-5328 (May 1996)	
	56	Bertrand, et al., <i>Induction of a Common Pathway of Apoptosis by Staurosporine, Experimental Cell Research</i> , Vol. 211, pp. 314-321 (1994)	
	57	Boustany, R-M, et al., <i>Seizures, Depression and Dementia in Teenagers with Batten Disease, J. Inher. Metab. Dis.</i> , Vol. 16, pp. 252-255 (1993)	
	58	Griffith, et al., <i>Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege, Science</i> , Vol. 270, pp. 1189-1193 (November 17, 1995)	
	59	Griffith, et al., <i>CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance, Immunity</i> , Vol. 5, pp. 7-16 (July 1996)	
	60	Hannun, Yusuf A., <i>Functions of Ceramide in Coordinating Cellular Responses to Stress, Science</i> , Vol. 274, pp. 1855-1859 (December 13, 1996)	
	61	Janes, et al., <i>A model of Batten disease protein CLN3: Functional implications from homology and mutations, Federation of European Biochemical Societies</i> , Vol. 399, pp. 75-77 (1996)	
	62	Kulkarni, et al., <i>Serum deprivation induces apoptotic cell death in a subset of Balb/c 3T3 fibroblasts, Journal of Cell Science</i> , Vol. 107, pp. 1169-1179 (1994)	
	63	Lane, et al., <i>Apoptosis as the Mechanism of Neurodegeneration in Batten's Disease, Journal of Neurochemistry</i> , Vol. 67, No. 2, pp. 677-683 (1996)	
	64	Liu, et al., <i>Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c, Cell</i> , Vol. 86, pp. 147-157 (July 12, 1996)	
	65	Mitchison, et al., <i>Genomic Structure and Complete Nucleotide Sequence of the Batten Disease Gene, CLN3, Genomics</i> , Vol. 40, pp. 346-350 (1997)	
	66	Peña, et al., <i>Stress-Induced Apoptosis and the Sphingomyelin Pathway, Biochemical Pharmacology</i> , Vol. 53, pp. 615-621 (1997)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet	3	of	3	Application Number	09/830,045	
				Filing Date	April 20, 2001	
				First Named Inventor	Rose-Mary N. Boustany	
				Group Art Unit	Unknown	
				Examiner Name	Unknown	
				Attorney Docket Number	5405.225	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T
	67	Puranam, et al., <i>Upregulation of Bcl-2 and Elevation of Ceramide in Batten Disease</i> , <u>Neuropediatrics</u> , Vol. 28, pp. 37-41 (1997)				
	68	Smyth, et al., <i>prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2</i> , <u>Biochem. J.</u> , Vol. 316, pp. 25-28 (1996)				
	69	The International Batten Disease Consortium, <i>Isolation of a Novel Gene Underlying Batten Disease</i> , <u>CLN3, Cell</u> , Vol. 82, pp. 949-957 (September 22, 1995)				
	70	White, Eileen, <i>Life, death, and the pursuit of apoptosis</i> , <u>Genes & Development</u> , Vol. 10, pp. 1-15 (1996)				

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.